BioTech Weekly - Jun 16-22, 2025 (Week 25)

🚨 BioTech Breakthroughs You Can't Miss – This Week in 7:30min Minutes 🎧This week’s roundup features 14 key articles across 5 major categories (Strategic & Leadership Updates, Financing & Transactions, Clinical & Regulatory Developments, Policy & Market Shifts, Industry Vision & Commentary). From FDA policy moves and major layoffs to new funding rounds and pediatric trials, this summary highlights the momentum and challenges shaping biotech today.🔬 Whether you're an investor, scientist, or biotech enthusiast, this episode is your shortcut to staying informed.#biotech #pharmaceuticals #healthcareinnovation #podcast #drugdevelopment #clinicaltrials #biotechnews #lifesciences #investors #healthtechSources🔍 Strategic Moves & Leadership Updates👉 BMS banks on Wall Street vet for long-term strategy guidance— Chutes & Ladders👉 FDA's CBER head dons extra hats with new CMO, CSO titles👉 Isomorphic Labs taps CMO, plants roots in Boston💰 Financing & Transactions👉 PharmAla Files Preliminary Base Shelf Prospectus👉 Aptose and Hanmi Enter New Loan Agreement to Advance Development of Tuspetinib👉 PSYENCE GROUP INC. Announces Offering of up to C$600,000🧪 Clinical & Regulatory News👉 LabPMM® Receives New York State Approval for the NPM1 MRD Assay👉 enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)👉 Biogen Initiates Phase 3 Pediatric Study of Omaveloxolone⚖️ Policy & Market Shifts👉 FDA blocks new clinical trials that ship cells from US to China👉 Industry reacts as FDA reportedly puts cell and gene therapy chief on leave👉 Prothena lays off 63% of employees after phase 3 trial fail👉 Syncona shifts biotech investment strategy amid tough market🌍 Long-Term Vision👉 The World Can’t Wait: Biopharma’s “Gold

There are no comments yet.

Please log in to write the first comment.